^
    5d
    Pathological complete response to perioperative treatment with darolutamide plus ADT in locally advanced prostate cancer without PTEN or RB1 loss: a case report. (PubMed, Front Pharmacol)
    The initial intensified systemic regimen is the doublet therapy of Darolutamide (600 mg orally twice daily) and goserelin (10.8 mg administered subcutaneously every 3 months). During 20 months of follow-up, the patient maintained an undetectable PSA, and had no radiographic evidence of disease relapse with well treatment tolerance. This case suggests that darolutamide plus ADT, administered as a tailored perioperative intensified systemic strategy, may induce a rapid and profound PSA response and may be associated with pCR in selected patients with very high-risk LAPC, while further investigation is warranted.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1)
    |
    Nubeqa (darolutamide) • goserelin acetate
    6d
    Bilateral invasive lobular breast carcinoma with synchronous gastric metastasis and orbital pseudotumor mimicking metastasis: a case report. (PubMed, Discov Oncol)
    This case demonstrates a rare gastric metastasis in bilateral ILC in addition to a diagnostic challenge of differentiating orbital metastasis from pseudotumor.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDH1 (Cadherin 1)
    |
    ER positive
    |
    paclitaxel • tamoxifen • goserelin acetate
    7d
    Effect of GnRH Agonist in FET (clinicaltrials.gov)
    P1/2, N=122, Not yet recruiting, Assiut University
    New P1/2 trial
    8d
    RADVAN: Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (clinicaltrials.gov)
    P3, N=372, Recruiting, Sun Yat-sen University | Active, not recruiting --> Recruiting
    Enrollment open
    |
    triptorelin • goserelin acetate
    13d
    ETCTN 10553: Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2027 --> Nov 2026 | Trial primary completion date: Apr 2027 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)
    26d
    Successful management of refractory hyperprolactinemia secondary to ectopic prolactin-secreting disseminated peritoneal leiomyomatosis via surgical resection and postoperative leuprorelin therapy: a rare case report. (PubMed, Gynecol Pelvic Med)
    She received bromocriptine (up to 5 mg/day) for 6 months without response. Clinicians should consider extrapituitary prolactin-secreting lesions in patients with treatment-refractory hyperprolactinemia. Genetic evaluation may further elucidate the pathogenesis of such rare entities.
    Journal
    |
    PRLR (Prolactin Receptor 2)
    |
    leuprolide acetate for depot suspension
    27d
    IFOCOS: Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients. (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    |
    tamoxifen • goserelin acetate
    1m
    Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)" (clinicaltrials.gov)
    P=N/A, N=1905, Completed, Takeda | Recruiting --> Completed
    Trial completion
    |
    AR (Androgen receptor)
    |
    leuprolide acetate for depot suspension
    1m
    ADENOFERT: Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial features: a prospective, randomized study (2024-516089-12-00)
    P4, N=500, Recruiting, Azienda Ospedaliero Universitaria Di Modena | Not yet recruiting --> Recruiting
    Enrollment open
    |
    leuprolide acetate for depot suspension
    1m
    A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=88, Recruiting, TerSera Therapeutics LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    |
    goserelin acetate
    1m
    Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    Eligard (leuprolide acetate) • Viadur (leuprorelin implant)
    1m
    Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Feb 2027
    Trial completion date
    |
    Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • Viadur (leuprorelin implant)